Cyberonics Banking On Appeals To Avoid VNS Randomized Trial Requirement
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics will defer a new randomized trial of its VNS Therapy depression indication until it can determine whether an appeal of FDA's recent not-approvable decision may be successful
You may also be interested in...
Lifecore Renova Dental Implant Sales Make Impression With Investors
Strong sales of Lifecore Biomedical's recently unveiled Renova internal hex dental implant system are aiding double-digit revenue growth at the firm and helped drive a 43.4% August stock gain to $7.10
Lifecore Renova Dental Implant Sales Make Impression With Investors
Strong sales of Lifecore Biomedical's recently unveiled Renova internal hex dental implant system are aiding double-digit revenue growth at the firm and helped drive a 43.4% August stock gain to $7.10
Brain Blood Clot Remover Clears FDA; Comparison Found In Stroke Drug Study
Concentric Medical averted a randomized clinical trial requirement for Merci Retriever by convincing FDA that a single-arm study backs 510(k) clearance of the embolic retrieval system